CMR for Prognosis Assessment in NSTEMI
Launched by HEART CENTER LEIPZIG - UNIVERSITY HOSPITAL · Apr 24, 2018
Trial Information
Current as of May 15, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: Patients are eligible for the study if they have: 1) ischemic symptoms in accordance with a possible NSTEMI diagnosis; 2) elevated cardiac troponin levels above the 99th percentile; and 3) identifiable culprit lesion during early invasive coronary angiography with performed PCI.
- • Exclusion Criteria: 1) STEMI; 2) presence of cardiogenic shock; 3) no identifiable culprit lesion or culprit lesion ineligible for PCI; 4) indication for acute bypass surgery; 5) age less than 18 years or more than 90 years; 6) pregnancy; and 7) typical contraindications to CMR (e.g. severe claustrophobia, implanted pacemakers and internal cardioverter defibrillators, cerebral or intracranial metallic implants, known allergy to gadolinium and creatinine clearance \<30 mL/min).
About Heart Center Leipzig University Hospital
Heart Center Leipzig - University Hospital is a leading medical institution specializing in cardiovascular care and research. Renowned for its commitment to advancing heart health, the center integrates cutting-edge clinical practices with innovative research initiatives. As a prominent clinical trial sponsor, it focuses on developing and evaluating new therapeutic strategies and technologies aimed at improving patient outcomes in cardiovascular diseases. The Heart Center Leipzig is dedicated to fostering collaboration between clinicians, researchers, and industry partners to enhance the understanding and treatment of heart conditions, ultimately contributing to global advancements in cardiovascular medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials